Head to Head Contrast: Sonendo (SONX) and Its Rivals

Sonendo (NYSE:SONX) is one of 153 public companies in the “Medical Devices” industry, but how does it contrast to its peers? We will compare Sonendo to related businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends.

Volatility and Risk

Sonendo has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Sonendo’s peers have a beta of 0.87, meaning that their average share price is 13% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sonendo and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sonendo	$43.87 million	-$60.92 million	-0.13
Sonendo Competitors	$1.02 billion	$88.20 million	85.75

Sonendo’s peers have higher revenue and earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

28.7% of Sonendo shares are held by institutional investors. Comparatively, 28.2% of shares of all “Medical Devices” companies are held by institutional investors. 6.4% of Sonendo shares are held by company insiders. Comparatively, 23.9% of shares of all “Medical Devices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sonendo and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonendo	-138.88%	-121.92%	-58.04%
Sonendo Competitors	-82.86%	-48.37%	-19.19%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Sonendo and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0	3	1	0	2.25
Sonendo Competitors	274	1343	1894	53	2.48

Sonendo presently has a consensus price target of $1.88, suggesting a potential upside of 2,100.70%. As a group, “Medical Devices” companies have a potential upside of 46.55%. Given Sonendo’s higher possible upside, research analysts clearly believe Sonendo is more favorable than its peers.

Summary

Sonendo peers beat Sonendo on 10 of the 13 factors compared.

Sonendo Company Profile

Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California.